683 Capital Management LLC Acquires Shares of 90,000 Becton, Dickinson and Company $BDX

683 Capital Management LLC acquired a new stake in Becton, Dickinson and Company (NYSE:BDX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 90,000 shares of the medical instruments supplier’s stock, valued at approximately $17,466,000. Becton, Dickinson and Company makes up about 0.8% of 683 Capital Management LLC’s holdings, making the stock its 18th largest holding.

A number of other large investors have also recently made changes to their positions in the business. Crux Wealth Advisors lifted its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after buying an additional 49 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Becton, Dickinson and Company by 1.7% in the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock valued at $627,000 after buying an additional 53 shares in the last quarter. Camelot Portfolios LLC lifted its stake in shares of Becton, Dickinson and Company by 1.5% in the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after buying an additional 54 shares in the last quarter. McElhenny Sheffield Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 3.6% in the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after buying an additional 55 shares in the last quarter. Finally, Atlantic Union Bankshares Corp lifted its stake in shares of Becton, Dickinson and Company by 0.9% in the fourth quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after buying an additional 57 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $151.48, for a total transaction of $166,628.00. Following the sale, the executive vice president owned 14,272 shares of the company’s stock, valued at $2,161,922.56. This trade represents a 7.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,013 shares of company stock valued at $593,434 in the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $141.58 on Thursday. The firm has a 50-day moving average of $149.37 and a 200-day moving average of $172.86. The company has a market cap of $39.01 billion, a P/E ratio of 35.84, a P/E/G ratio of 10.28 and a beta of 0.22. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. During the same quarter in the prior year, the company posted $3.35 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be issued a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 3.0%. The ex-dividend date is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Analysts Set New Price Targets

A number of research analysts have weighed in on BDX shares. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. TD Cowen dropped their price objective on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a research note on Monday, May 4th. Argus lowered their target price on shares of Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating for the company in a report on Monday, March 23rd. Wells Fargo & Company increased their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Finally, The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $181.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.